Asset Details
Do you wish to reserve the book?
Precision therapy for lymphoma—current state and future directions
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Precision therapy for lymphoma—current state and future directions
Do you wish to request the book?
Precision therapy for lymphoma—current state and future directions
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Precision therapy for lymphoma—current state and future directions
2014
Overview
Key Points
Lymphomas exhibit heterogeneous genomic alterations, both across and within histological subtypes
The molecular heterogeneity underlying lymphoma accounts, at least in part, for variable responses to treatment
Lymphoma investigators should incorporate biomarkers into clinical trials to facilitate the clinical development of molecularly targeted therapeutics
Techniques for identifying and reporting genomic alterations must be optimized and standardized so that mechanism-based therapies can be effectively applied to the clinical care of lymphoma patients
Lymphoma represents a heterogeneous disease both across and within histological subtypes. The future for the treatment of patients with lymphoma will involve matching a targeted therapy to the unique genetic and molecular composition of each lymphoma. This Review discusses biomarkers that can guide treatment decisions for patients with lymphoma, and explore the challenges and strategies for making biomarker-driven personalized medicine a reality in the cure and management of this disease.
Modern advances in genomics and cancer biology have produced an unprecedented body of knowledge regarding the molecular pathogenesis of lymphoma. The diverse histological subtypes of lymphoma are molecularly heterogeneous, and most likely arise from distinct oncogenic mechanisms. In parallel to these advances in lymphoma biology, several new classes of molecularly targeted agents have been developed with varying degrees of efficacy across the different types of lymphoma. In general, the development of new drugs for treating lymphoma has been mostly empiric, with a limited knowledge of the molecular target, its involvement in the disease, and the effect of the drug on the target. Thus, the variability observed in clinical responses likely results from underlying molecular heterogeneity. In the era of personalized medicine, the challenge for the treatment of patients with lymphoma will involve correctly matching a molecularly targeted therapy to the unique genetic and molecular composition of each individual lymphoma. In this Review, we discuss current and emerging biomarkers that can guide treatment decisions for patients with lymphoma, and explore the potential challenges and strategies for making biomarker-driven personalized medicine a reality in the cure and management of this disease.
Publisher
Nature Publishing Group UK,Nature Publishing Group
